Intralesional chemotherapy for Kaposi's sarcoma.

Area of Science:

• Oncology
• Dermatology

Background:

• Kaposi's sarcoma often presents with skin lesions.
• Effective and safe treatment options for cutaneous Kaposi's sarcoma are needed.

Purpose of the Study:

• To evaluate the efficacy and safety of intralesional chemotherapy for skin Kaposi's sarcoma.

Main Methods:

• 12 patients with skin Kaposi's sarcoma received intralesional chemotherapy.
• Vincristine or bleomycin was administered at a usual dose of 0.1 mg per site.
• Treatment was administered over a 36-month period.

Main Results:

• A total of 93 injected nodules were treated.
• 74 complete regressions and 19 partial regressions were observed.
• No significant local or systemic toxicity was reported.

Conclusions:

• Intralesional chemotherapy with vincristine or bleomycin is a highly effective treatment for cutaneous Kaposi's sarcoma.
• This method demonstrates a favorable safety profile with minimal toxicity.
• Local administration offers a promising therapeutic strategy for managing skin manifestations of Kaposi's sarcoma.